State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China.
Chem Asian J. 2019 Jan 4;14(1):130-134. doi: 10.1002/asia.201801461. Epub 2018 Nov 26.
Peptidyl-prolyl cis-trans isomerase Pin1 plays a crucial role in the development of human cancers. Recently, we have disclosed that Pin1 regulates the biogenesis of miRNA, which is aberrantly expressed in HCC and promotes HCC progression, indicating the therapeutic role of Pin1 in HCC therapy. Here, 7-(benzyloxy)-3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4H-chromen-4-one (AF-39) was identified as a novel Pin1 inhibitor. Biochemical tests indicate that AF-39 potently inhibits Pin1 activity with an IC values of 1.008 μm, and also displays high selectivity for Pin1 among peptidyl prolyl isomerases. Furthermore, AF-39 significantly suppresses cell proliferation of HCC cells in a dose- and time-dependent manner. Mechanistically, AF-39 regulates the subcellular distribution of XPO5 and increases miRNAs biogenesis in HCC cells. This work provides a promising lead compound for HCC treatment, highlighting the therapeutic potential of miRNA-based therapy against human cancer.
肽基脯氨酰顺反异构酶 Pin1 在人类癌症的发展中起着至关重要的作用。最近,我们已经揭示了 Pin1 调节 miRNA 的生物发生,miRNA 在 HCC 中异常表达并促进 HCC 的进展,这表明 Pin1 在 HCC 治疗中有治疗作用。在这里,7-(苄氧基)-3,5-二羟基-2-(4-甲氧基苯基)-8-(3-甲基-2-丁烯-1-基)-4H-色烯-4-酮(AF-39)被鉴定为一种新型的 Pin1 抑制剂。生化测试表明,AF-39 强烈抑制 Pin1 的活性,IC 值为 1.008μm,并且在肽基脯氨酰异构酶中对 Pin1 也具有高选择性。此外,AF-39 以剂量和时间依赖的方式显著抑制 HCC 细胞的增殖。在机制上,AF-39 调节 XPO5 的亚细胞分布并增加 HCC 细胞中 miRNA 的生物发生。这项工作为 HCC 治疗提供了一个有前途的先导化合物,突出了基于 miRNA 的治疗对人类癌症的治疗潜力。